Article
Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy - 1 Feb 2005
Kriengkauykiat Jane, Porter Edith, Lomovskaya Olga, Wong-Beringer Annie
Abstract excerpt
Fluoroquinolone-resistance in Pseudomonas aeruginosa may be due to efflux pump overexpression (EPO) and/or target mutations. EPO can result in multidrug resistance (MDR) due to broad substrate specificity of the pumps. MC-04,124, an efflux pump inhibitor (EPI) shown to significantly potentiate activity of levofloxacin in P. aeruginosa, was used to examine the prevalence of EPO in clinical isolates. MICs were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.